Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross PI3K Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.592

    Phosphoinositide 3-kinase (PI3K) Inhibitors

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.592 alerts

    Get alerted when Policy 5.01.592 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity review and prior authorization for specified oral PI3K pathway inhibitors used for oncology, immunologic, and PIK3CA-related overgrowth conditions. Coverage depends on drug-specific diagnosis, age, mutation or biomarker findings, prior therapy, combination therapy, prescriber specialty, dosing, and response criteria.

    Policy Summary
    PayerPremera Bluecross
    PolicyPhosphoinositide 3-kinase (PI3K) Inhibitors
    Policy CodePolicy 5.01.592
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the drug-specific covered indication and all applicable clinical criteria, including age, diagnosis, biomarker or mutation status, prior treatment, specialist involvement, and dose limits.
    SourceLink
    POLICY UPDATE CHANGES

    The 2021 update added coverage criteria for umbralisib for marginal zone lymphoma and follicular lymphoma.

    The 2022 update removed duvelisib coverage for relapsed or refractory follicular lymphoma after the manufacturer voluntarily withdrew the indication.

    The 2022 update removed copanlisib coverage for chronic lymphocytic leukemia and small lymphocytic lymphoma because the drug was not FDA approved or recommended by NCCN for those conditions.

    The 2022 update added coverage for alpelisib products Vijoice and Piqray for PIK3CA-related overgrowth spectrum.

    The 2023 update added coverage criteria for leniolisib for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric individuals age 12 years and older.

    The 2024 update added coverage criteria for capivasertib for certain individuals with breast cancer.

    The 2024 update removed idelalisib coverage criteria for certain follicular lymphoma and small lymphocytic lymphoma uses because those indications were removed from prescribing information.

    The 2024 update revised alpelisib coverage criteria to include certain premenopausal and perimenopausal women with breast cancer.

    Added coverage criteria for Truqap (capivasertib) in adults with metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient.

    Removed coverage criteria for Aliqopa (copanlisib) because the medication has been discontinued.

    Removed HCPCS code J9057 from the policy.

    Changed the initial authorization period for all other reviews of oral drugs listed in the policy from 3 months to 6 months.

    Limited the Piqray (alpelisib) breast-cancer dose to 300 mg once daily.

    Removed the ECOG performance status 0 or 1 requirement from Itovebi (inavolisib) criteria.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsMaximum initial authorization period
    12 monthsMaximum reauthorization period
    7Named PI3K-pathway drugs with criteria
    2 yearsYoungest Vijoice treatment age
    6Oral drugs managed through pharmacy benefit
    1HCPCS codes removed in update

    Coverage Criteria

    Copiktra initial therapy

    Covered when all criteria are met.

    Copiktra (duvelisib) for CLL/SLL: Relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; age 18 years or older; at least two prior systemic therapies.Age ≥18 years; ≥2 prior systemic therapies

    May be considered medically necessary.

    Itovebi initial therapy

    Covered when all criteria are met.

    Itovebi (inavolisib) for breast cancer: Adult with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer; disease progression after at least one line of endocrine therapy in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy; used with Ibrance (palbociclib) and fulvestrant as first-line therapy; no disease progression on or following another PI3K inhibitor; prescribed by or in consultation with an oncologist; dose limited to 9 mg once daily.Age ≥18 years; 9 mg once daily

    All listed conditions are required.

    Joenja initial therapy

    Covered when all criteria are met.

    Joenja (leniolisib) for APDS: Activated phosphoinositide 3-kinase delta syndrome; age 12 years or older; documented APDS-associated PI3K delta gene mutation with a documented variant in either PIK3CD or PIK3R1; prescribed by or in consultation with an oncologist, medical geneticist, or hematologist; dose limited to 140 mg per day taken as 70 mg twice daily.Age ≥12 years; 140 mg/day maximum

    All listed conditions are required.

    Piqray breast cancer initial therapy

    Covered when all criteria are met.

    Piqray (alpelisib) for breast cancer: Age 18 years or older; HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer detected by an FDA-approved test; progression on or after an endocrine-based regimen; used in combination with fulvestrant; dose limited to 300 mg once daily.Age ≥18 years; 300 mg once daily maximum

    All listed conditions are required.

    Piqray PROS initial therapy

    Covered when all criteria are met.

    Piqray (alpelisib) for PROS: Age 18 years or older; diagnosed with PIK3CA-related overgrowth spectrum; at least one target lesion identified on imaging; documented PIK3CA gene mutation; prescribed by or in consultation with an oncologist, geneticist, or hematologist; dose limited to 250 mg once daily.Age ≥18 years; 250 mg once daily maximum; ≥1 target lesion

    All listed conditions are required.

    Truqap prostate cancer initial therapy

    Covered when all criteria are met.

    Truqap (capivasertib) for prostate cancer: Adult age 18 years or older with metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient; used with abiraterone, prednisone, and androgen deprivation therapy documented by concurrent GnRH analog therapy or prior bilateral orchiectomy; dose limited to 400 mg twice daily for 4 days followed by 3 days off.Age ≥18 years; 400 mg twice daily for 4 days, then 3 days off

    All listed combination treatments are required.

    Truqap breast cancer initial therapy

    Covered when all criteria are met, including one of the final alternatives.

    Truqap (capivasertib) for breast cancer

    • One sequencing or biomarker alternative

      • Piqray intolerance: Tried Piqray and had intolerance without disease progression.
      • Non-Piqray-sensitive mutation: Has a specific solitary AKT1 or PTEN mutation not sensitive to Piqray.

    Vijoice initial therapy

    Covered when all criteria are met.

    Vijoice (alpelisib) for PROS: Age 2 years or older; diagnosed with PIK3CA-related overgrowth spectrum; at least one target lesion identified on imaging; prescribed by or in consultation with an oncologist, geneticist, or hematologist.Age ≥2 years; ≥1 target lesion

    Dose limits vary by age: 50 mg once daily for ages 2-5, 125 mg once daily for ages 6-17, and 250 mg once daily for age 18 or older.

    Zydelig initial therapy

    Covered when all criteria are met.

    Zydelig (idelalisib) for relapsed CLL: Relapsed chronic lymphocytic leukemia; used in combination with rituximab for an individual for whom rituximab alone would be appropriate because of other comorbidities; dose limited to 300 mg per day taken as 150 mg twice daily.300 mg/day maximum

    Zydelig is not indicated or recommended for first-line treatment.

    All uses of drugs in this policy for conditions not outlined in the policy are considered investigational and may not be covered. Coverage is limited to the drug-specific indications and criteria described in this policy.

    Zydelig (idelalisib) is not indicated or recommended for first-line treatment of any individual. The policy provides coverage only for specified relapsed chronic lymphocytic leukemia treatment in combination with rituximab when the applicable criteria are met.

    Coding Information

    Removed HCPCS CodeHCPCS
    J9057HCPCS code removed from the policy

    Provider Actions and Authorization Rules

    Prior Authorization

    Drug-Specific Prior Authorization Required

    Prior authorization is required for coverage of each drug under this policy. The submitted documentation must support the requested drug’s covered indication and all applicable drug-specific clinical criteria.

    • Provide documentation addressing the applicable age, diagnosis, biomarker, prior-treatment, combination-therapy, prescriber, dose, and response requirements.
    Prior Authorization

    Authorization Duration

    Initial authorization for drugs in this policy may be approved for up to 6 months. Reauthorization may be approved for up to 12 months when the drug-specific coverage criteria are met and the required response documentation is provided.

    • Copiktra, Itovebi, Joenja, Piqray for breast cancer, Truqap, and Zydelig: reauthorization up to 12 months with criteria met and positive clinical response.
    • Piqray for PROS and Vijoice: reauthorization up to 12 months with criteria met and documented reduction in the sum of measurable target lesion volume from baseline.

    Clinical Background

    PI3K inhibitors block one or more enzymes in an intracellular signaling pathway involved in cell growth. This policy addresses selected uses of these agents across hematologic malignancies, breast and prostate cancers, activated PI3K-delta syndrome, and PIK3CA-related overgrowth spectrum. Coverage is subject to drug-specific requirements for diagnosis, age, mutation or biomarker findings, prior and combination therapy, specialist involvement, dosing, and treatment response.

    Definitions and Clinical Terms

    HER2-negative
    DefinitionHER2-negative means 0 or 1+ intensity on immunohistochemical testing.
    2+ resultA 2+ immunohistochemical result qualifies when there is no amplification on in situ hybridization.
    Testing basisHER2 status is determined using immunohistochemical testing and, when applicable, in situ hybridization.
    Activated phosphoinositide 3-kinase delta syndrome (APDS)
    SyndromeActivated phosphoinositide 3-kinase delta syndrome (APDS) is associated with PI3K delta gene mutations.
    Required findingThe policy requires a documented APDS-associated PI3K delta gene mutation.

    Initial Therapy Framework

    Initial authorization framework

    Initial coverage is available only when the requested drug is used for a covered indication and all applicable criteria are met.

    Drug-specific initial authorization: The requested drug must be used for a covered diagnosis and satisfy all applicable drug-specific criteria, including age, biomarker or mutation status, prior therapy, required combination therapy, specialist involvement, and dose limits.Initial authorization up to 6 months

    All other uses are considered investigational.

    Continuation and Reauthorization

    General reauthorization

    Reauthorization may be approved when all criteria are met.

    General continuation: The drug-specific coverage criteria continue to be met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.Up to 12 months

    Applies to Copiktra, Itovebi, Joenja, Piqray for breast cancer, Truqap, and Zydelig.

    Piqray PROS and Vijoice reauthorization

    Reauthorization may be approved when all criteria are met and objective response is documented.

    PROS continuation: For Piqray used for PROS and Vijoice, drug-specific coverage criteria continue to be met and chart notes demonstrate a reduction in the sum of measurable target-lesion volume from baseline.Up to 12 months

    Step Therapy Requirement

    StepRequired sequencingAlternative pathway
    1For Truqap (capivasertib) in HR-positive, HER2-negative advanced or metastatic breast cancer, the individual must have tried Piqray (alpelisib) and experienced intolerance without disease progression. The individual must not have experienced disease progression on or following another PI3K/AKT/PTEN inhibitor.The Piqray trial is not required when the individual has a specific solitary AKT1 or PTEN mutation that is not sensitive to Piqray.

    Drug-Specific Quantity Limits

    Itovebi (inavolisib)
    DrugItovebi (inavolisib)
    Maximum dose9 mg once daily.
    Policy useThe dose is limited to 9 mg once daily for the covered breast cancer indication.
    Joenja (leniolisib)
    DrugJoenja (leniolisib)
    Daily dose140 mg per day.
    AdministrationTaken as 70 mg twice daily.
    Policy Summary
    PayerPremera Bluecross
    PolicyPhosphoinositide 3-kinase (PI3K) Inhibitors
    Policy CodePolicy 5.01.592
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the drug-specific covered indication and all applicable clinical criteria, including age, diagnosis, biomarker or mutation status, prior treatment, specialist involvement, and dose limits.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and Authorization RulesClinical BackgroundDefinitions and Clinical TermsInitial Therapy FrameworkContinuation and ReauthorizationStep Therapy RequirementDrug-Specific Quantity Limits
    Billing Rule

    Six-Month Initial Authorization

    For all other reviews of listed oral drugs, the initial authorization period was updated from 3 months to 6 months.

    • Apply the 6-month initial authorization period to applicable oral drugs other than the specifically identified review categories.
    Step Therapy

    Truqap Breast Cancer Sequencing Requirement

    For Truqap breast cancer therapy, document the required sequencing or alternative pathway involving Piqray. The individual must not have experienced disease progression on or following another PI3K/AKT/PTEN inhibitor, such as Piqray.

    • Document either intolerance to Piqray without disease progression, or a specific solitary AKT1 or PTEN mutation that is not sensitive to Piqray.
    Documentation Required

    Office Visit Documentation

    Submit office visit notes that document the condition being treated and the clinical information supporting the request.

    • Diagnosis
    • Relevant history
    • Physical examination or evaluation
    • Medication history
    Documentation Required

    Medical Necessity Records

    The medical records submitted for review must document that the applicable medical-necessity criteria are met.

    • Include records sufficient to establish the covered indication and each applicable criterion for the requested drug.
    Prior Authorization

    Document Response for Reauthorization

    Reauthorization requires documentation that the individual continues to show a positive clinical response to therapy. For Piqray used for PROS and Vijoice, objective response must also be documented.

    • For Piqray for PROS and Vijoice, document a reduction in the sum of measurable target lesion volume from baseline.
    Denial Risk

    Unlisted Indication

    Use of a drug for a condition not outlined in this policy is considered investigational and may be denied.

    • Coverage remains subject to the product’s U.S. Food and Drug Administration dosage and administration prescribing information.
    Denial Risk

    Drug-Specific Criteria Not Met

    Coverage may be denied when the drug-specific criteria are not met or are not adequately documented.

    • Age requirement
    • Covered diagnosis and disease status
    • Required biomarker or mutation
    • Prior-treatment or disease-progression requirement
    • Required combination therapy or sequencing
    • Prescriber or specialist requirement
    • Dose limitation
    Denial Risk

    Insufficient Response for Reauthorization

    Continuation coverage may be denied when reauthorization records do not demonstrate a positive clinical response or, where required, an objective response.

    • Submit current chart notes supporting continued benefit from therapy.
    • For Piqray for PROS and Vijoice, include objective target-lesion volume measurements compared with baseline.
    Denial Risk

    Zydelig First-Line Use

    Zydelig is not indicated and is not recommended for first-line treatment of any individual.

    • Zydelig coverage described in this policy is for relapsed CLL in combination with rituximab when rituximab alone would otherwise be appropriate because of comorbidities.
    Note

    Aliqopa Discontinued

    Coverage criteria for Aliqopa (copanlisib) were removed because the medication has been discontinued.

    • Do not submit new requests under the removed Aliqopa coverage criteria.
    • HCPCS code J9057 was also removed from the policy.
    Acceptable variants
    The documented variant must be in either PIK3CD or PIK3R1.
    PIK3CA-related overgrowth spectrum (PROS)
    DisorderPIK3CA-related overgrowth spectrum (PROS) is a disorder caused by a PIK3CA mutation.
    Required lesionThe policy requires at least one target lesion identified on imaging.
    Mutation findingA documented PIK3CA gene mutation is required for Piqray treatment of PROS.
    PI3K-pathway alteration
    PIK3CAA PIK3CA mutation is a covered biomarker in applicable indications.
    Breast cancer alterationsCovered alterations may include one or more PIK3CA, AKT1, or PTEN alterations.
    PTEN disease statePTEN deficiency is a covered disease-state alteration for the specified prostate cancer indication.
    PI3K/AKT/mTOR pathway
    PathwayThe PI3K/AKT/mTOR pathway is an important intracellular signaling pathway.
    FunctionsIt is involved in cellular growth control, metabolism, and translation initiation.
    Potential effect of inhibitionInhibition of components of the pathway may result in tumor suppression.
    Class I PI3K isoforms
    SubunitClass I PI3Ks have a catalytic subunit known as p110.
    Alpha and betaThe p110 catalytic subunit has alpha and beta isoforms.
    Gamma and deltaThe p110 catalytic subunit also has gamma and delta isoforms.
    PIK3CA-related overgrowth spectrum (PROS)
    Disorder groupPROS is a heterogeneous group of disorders.
    Clinical featuresThe disorders are associated with vascular malformations and segmental overgrowth.
    Disease coursePROS is characterized by early-onset, progressive symptoms with high morbidity and mortality.
    Activated phosphoinositide 3-kinase delta syndrome (APDS)
    SyndromeAPDS is associated with a confirmed activating PI3K-delta mutation.
    Genetic confirmationThe policy requires a documented variant in either PIK3CD or PIK3R1.
    Population describedJoenja is indicated for adults and pediatric individuals 12 years of age and older with APDS.

    Objective reduction in measurable target-lesion volume is required.

    Piqray (alpelisib) for breast cancer
    DrugPiqray (alpelisib) for breast cancer.
    Maximum dose300 mg once daily.
    Policy limitationThe breast cancer dose is limited to 300 mg once daily.
    Piqray (alpelisib) for PROS
    DrugPiqray (alpelisib) for PIK3CA-related overgrowth spectrum (PROS).
    Maximum dose250 mg once daily.
    Policy limitationThe PROS dose is limited to 250 mg once daily.
    Truqap (capivasertib)
    DrugTruqap (capivasertib)
    Dose400 mg twice daily.
    ScheduleTake for 4 days followed by 3 days off.
    Zydelig (idelalisib)
    DrugZydelig (idelalisib)
    Daily dose300 mg per day.
    AdministrationTaken as 150 mg twice daily.
    Vijoice (alpelisib), age 2–5 years
    DrugVijoice (alpelisib) for individuals aged 2–5 years.
    Maximum dose50 mg once daily.
    Age rangeApplies to ages 2 through 5 years.
    Vijoice (alpelisib), age 6–17 years
    DrugVijoice (alpelisib) for individuals aged 6–17 years.
    Maximum dose125 mg once daily.
    Age rangeApplies to ages 6 through 17 years.
    Vijoice (alpelisib), age 18 years and older
    DrugVijoice (alpelisib) for individuals aged 18 years and older.
    Maximum dose250 mg once daily.
    Age rangeApplies to individuals age 18 years and older.
    Piqray (alpelisib)
    DrugPiqray (alpelisib)
    Dose limit300 mg once daily.
    Policy updateThe breast cancer dose was limited to 300 mg once daily.